A landmark international clinical trial published in The New England Journal of Medicine demonstrates that genetic testing could fundamentally change how breast cancer treatment is approached. The RxPONDER trial, involving over 5,000 patients across multiple countries, found that approximately 70% of intermediate-risk breast cancer patients achieve equivalent survival outcomes without chemotherapy.
The Oncotype DX test, a 21-gene assay, enables clinicians to identify which patients can safely forgo the debilitating side effects of chemotherapy while maintaining survival rates above 93%. According to lead researcher Dr. Joseph Sparano from Montefiore Einstein Comprehensive Cancer Center, postmenopausal women with intermediate recurrence scores showed no survival benefit from adding chemotherapy to hormone therapy alone.
These findings could spare up to 6,600 patients annually in the UK alone from unnecessary treatment toxicity while preserving clinical outcomes. The research underscores the growing importance of precision medicine in oncology, where genetic data guides individualized treatment decisions rather than one-size-fits-all protocols.
Read the full article on GMJ Newsroom.
Was this article helpful?
